Search results
Showing 1696 to 1710 of 2005 results for nice guidelines
Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)
This evidence summary has been updated and replaced by NICE guideline NG117.
Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)
This evidence summary has been updated and replaced by NICE guideline NG201.
Multiple long-term conditions: falls prevention advice (IND209)
This indicator has been removed following the publication of NICE guideline NG249.
SeQuent Please balloon catheter for in-stent coronary restenosis (MTG1)
This medical technologies guidance has been replaced by the recommendations in the NICE guideline on acute coronary syndromes.
Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)
This evidence summary has been updated and replaced by the NICE guideline CG178 (published February 2014).
This evidence summary has been updated and replaced by NICE guideline CG113 and subsequent surveillance reviews.
LATITUDE NXT Patient Management System for monitoring cardiac devices at home (MIB67)
NICE has developed a medtech innovation briefing (MIB) on the LATITUDE NXT Patient Management System for monitoring cardiac devices at home
This medical technologies guidance has been replaced by the recommendation on cardiac output monitoring in the NICE guideline on perioperative care in adults.
Active B12 assay for diagnosing vitamin B12 deficiency (MIB40)
NICE has developed a medtech innovation briefing (MIB) on the Active-B12 assay for diagnosing vitamin B12 deficiency
Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (TA93)
This guidance has been updated and replaced by NICE guideline NG151. The recommendations on raltitrexed have been withdrawn because its use is established clinical practice.
This evidence summary has been withdrawn because licensed products are now available and the off-label indication has been replaced by NICE guideline NG71.
Interventional procedures, IPG51 - Issued: March 2004 --> This guidance has been withdrawn as the use of this procedure is now covered in the NICE guideline on heavy menstrual bleeding: assessment and management. NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme.
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Show all sections
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.